Latest Pharmaceutical Companies News

Page 1 of 10
Mayne Pharma has agreed to a A$6.40-a-share cash takeover by Hungary’s Gedeon Richter, valuing the company’s equity at approximately A$604 million. The recommended scheme still depends on regulatory clearances, shareholder and court approval, and completion of Mayne’s international business sale.
Victor Sage
Victor Sage
17 Nov 2026
Hydration Pharmaceuticals sharply reduced Hydralyte LLC’s US operating loss in the September quarter after cutting costs and refocusing marketing. But weaker September trading, stock-outs, limited cash and an ununderwritten entitlement offer leave the turnaround unfinished.
Victor Sage
Victor Sage
11 Nov 2026
Alterity Therapeutics says it has begun operational preparations for a Phase 3 ATH434 trial after FDA minutes confirmed the proposed design and registrational pathway in Multiple System Atrophy. The company ended September with A$41.3 million in cash, while a new US patent extends protection for ATH434 to 2045.
Ada Torres
Ada Torres
30 Oct 2026
Clever Culture Systems has started FY27 with three APAS Independence sales to Novo Nordisk and AstraZeneca, while targeting eight first-half sales and evaluations. The sales momentum comes with $1.6 million of unsecured loans due in December and a proposed extension still to be secured.
Victor Sage
Victor Sage
30 Oct 2026
Avecho has resumed recruitment for the final cohort of its pivotal Phase III insomnia trial after an interim review supported continuing at the original 519-participant target. The biotechnology company is also pursuing international licensing while holding $5.3 million in cash.
Ada Torres
Ada Torres
28 Oct 2026
Clever Culture Systems has fully invoiced three APAS Independence sales in the first quarter of FY27 and expects customer commitments to lift first-half sales and evaluations to eight instruments. A new paid evaluation with a Top-20 pharmaceutical company could expand its base of major drugmakers to nine, although several milestones remain prospective.
Victor Sage
Victor Sage
28 Oct 2026
Mayne Pharma’s unaudited first-quarter revenue fell 2% to A$95.7 million, while underlying EBITDA dropped 52% as generic competition hit Dermatology. Strong prescription growth in Women’s Health and DistributeRx offered a partial counterweight, alongside progress on key legal disputes.
Victor Sage
Victor Sage
26 Oct 2026
Hydration Pharmaceuticals is asking eligible shareholders for up to A$1.43 million in fresh capital as it funds the next phase of its turnaround. The non-renounceable offer comes with free options, but is neither underwritten nor subject to a minimum subscription.
Ada Torres
Ada Torres
23 Oct 2026
Clever Culture Systems has appointed PSC Biotech as its sole sales agent for APAS Independence across pharmaceutical manufacturing markets in the US, Canada and Singapore. The agreement expands CCS’s reach beyond its direct focus on major global drugmakers, but any material revenue uplift is not expected before FY28.
Victor Sage
Victor Sage
14 Oct 2026
Compumedics Limited (ASX:CMP) returned to profit in FY26 as record revenue, stronger cash generation and a sharp rise in MEG and SaaS sales reshaped its earnings profile. The company enters FY27 with A$28.3 million of open orders, but lower gross margins and uneven US and European execution remain key tests.
Victor Sage
Victor Sage
30 Sept 2026
The Hydration Pharmaceuticals Company (ASX:HPC) has sharply reduced its operating losses, with Hydralyte LLC recording its first monthly EBITDA profit in August. The group remains loss-making overall, but improved margins and a lower cost base are beginning to show in the numbers.
Victor Sage
Victor Sage
29 Sept 2026
Recce Pharmaceuticals narrowed its operating loss to AUD 15 million in FY26, progressing Phase 3 trials for its anti-infective RECCE 327 and securing key patents and commercial partnerships.
Ada Torres
Ada Torres
31 Aug 2026

Browse the archive

Full archive